Procter & Gamble’s Dual-Pronged Strategy Amid Share Price Pressure

While its shares have faced a challenging year, consumer goods behemoth Procter & Gamble is executing a two-part offensive strategy. The company is simultaneously launching a major marketing campaign and taking regulatory action against a competitor, signaling a fight for market leadership rather than a defensive retreat. Investors are now questioning whether these moves can reverse the stock’s downward trajectory.

Regulatory Challenge Against a Competitor

In a move underscoring its aggressive stance on market competition, Procter & Gamble recently prompted a regulatory escalation. On Monday, the National Advertising Division (NAD) referred competitor Rascals International to the Federal Trade Commission (FTC) following a challenge initiated by P&G. The core allegation involves misleading advertising claims regarding “up to 12 hours of leakage protection” and allegedly fabricated “5-star reviews.”

Rascals International’s refusal to modify the contested claims led to the referral to the higher regulatory authority. This action is fundamentally about safeguarding the premium market position of P&G’s Pampers brand within the intensely competitive infant care segment.

Securing Prime Marketing Real Estate

Separately, on Tuesday, the corporation announced a significant three-year partnership with the Tour de France and the Tour de France Femmes avec Zwift. From 2025 through 2028, flagship brands including Pampers, Gillette, Venus, and Head & Shoulders will receive prominent placement during one of the world’s most-watched sporting events.

Should investors sell immediately? Or is it worth buying Procter & Gamble?

The strategic timing of this investment is notable. With P&G products already reaching nine out of ten households in France, this multi-million euro visibility campaign aims to further cement brand loyalty. The European market remains crucial for the conglomerate, and the Tour provides extended media exposure to a demographically attractive and affluent audience.

Valuation and the Path Forward

Despite these assertive strategic plays, P&G’s equity continues to trade under significant pressure. Since the start of the year, the share price has declined by approximately 21%, underperforming the expectations of many in the investment community.

Market analysts, however, see potential for recovery. The consensus average price target sits near 172 euros, implying an upside potential of over 15% from current levels. Some fundamental valuation models are even more bullish, assessing the stock’s fair value at around 185 euros.

The next critical test for the company arrives on January 21, 2026, with the release of its quarterly earnings. That report will reveal whether the new marketing initiatives resonated during the vital holiday shopping period. More broadly, it will indicate if this dual-pronged approach of enhanced brand visibility and aggressive competition defense is sufficient to catalyze a sustained turnaround for the storied company.